News

AZ spins out antibiotic R&D
Enlarge image

BusinessUK

AZ spins out antibiotic R&D

03.03.2015 - After weeks of speculation, AstraZeneca has announced its plans to spin out its early-stage antibiotic R&D. The decision marks the company’s aims to “sharpen its focus on three main therapy areas”.

The new stand-alone subsidiary company will likely be led by staff from AZ’s Innovative Medicines Unit. It will focus on the research and development of the early-stage antibiotic pipeline, including AZD0914, a novel gyrase inhibitor currently in Phase II for the treatment of gonorrhoea. The currently nameless spin-off will also receive a US$40m investment from AZ as a goodbye gift.

A week ago, industry experts from Fierce reported that AstraZeneca had tried and failed for more than a year to find someone to take over the division. The London-based company has decided to split it off, nevertheless. The move will impact approximately 95 employees based in the US. AZ hopes that some of the researchers impacted by the changes will take up roles in the new company, or in other parts of its own operations. “The decision does not affect the company’s late-stage small molecule infection programmes or MedImmune’s portfolio of biologic anti-infectives,” AZ said in a statement.


© european-biotechnology-news.com/um

http://www.european-biotechnology-news.com/news/news/2015-01/az-spins-out-antibiotic-rd.html

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

IVFUKEU

04.02.2015 In a historic move, the UK is set to become the first country to allow the creation of babies with the genetic material of three people – a mother, a father and a female mitochondrial donor.

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/news/news.html?cHash=8190681cb0ea9c9ddcb48c4293a426da&sort=desc

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MEDIGENE4.64 EUR7.16%
  • FORMYCON16.89 EUR4.07%
  • BIOFRONTERA1.99 EUR3.65%

FLOP

  • HBM102.00 CHF-2.86%
  • SYNGENTA327.00 CHF-2.15%
  • STRATEC BIOMEDICAL45.12 EUR-2.10%

TOP

  • WILEX3.17 EUR47.4%
  • EVOLVA1.70 CHF18.9%
  • MEDIGENE4.64 EUR16.0%

FLOP

  • MOLOGEN5.25 EUR-12.5%
  • SANTHERA98.45 CHF-10.2%
  • 4SC0.77 EUR-9.4%

TOP

  • SANTHERA98.45 CHF2417.9%
  • WILEX3.17 EUR395.3%
  • FORMYCON16.89 EUR119.4%

FLOP

  • CYTOS0.37 CHF-86.9%
  • MOLOGEN5.25 EUR-56.0%
  • PAION2.10 EUR-52.5%

No liability assumed, Date: 03.03.2015